Skip to main content

Table 1 Baseline patient characteristics and biomarker values

From: Treatment-related biomarkers in pulmonary hypertension patients on oral therapies

  Overall
N = 58
On therapy with ERA
N = 16
On therapy with PDE5i or sGCa
N = 17
On therapy with ERA + PDE5ib
N = 25
Age (years) 61.1 (46.1, 68.5) 61.6 (51.0, 68.1) 69.1 (61.1, 76.4) 51.2 (37.7, 63.9)
Female 52 (89.7%) 16 (100.0%) 14 (82.4%) 22 (88.0%)
Years since PAH diagnosis 6.7 (2.3, 10.7) 7.5 (2.8, 12.0) 5.9 (1.2, 10.9) 6.8 (2.7, 10.0)
6MWD (m) 427.9 (362.1, 487.4)
(N = 54)
413.8 (359.1, 461.0) 427.9 (351.1, 460.9)
(N = 15)
457.2 (369.0, 526.7)
(N = 23)
mPAP (mmHg) 40.3 (27.0, 49.3)
(N = 35)
39.8 (31.8, 48.3)
(N = 12)
29.2 (22.0, 37.0)
(N = 10)
46.7 (40.3, 50.0)
(N = 13)
PVR (WU) 5.1 (3.6, 6.3)
(N = 31)
5.1 (3.9, 6.2)
(N = 11)
3.6 (2.4, 3.7)
(N = 9)
6.0 (5.6, 6.9)
(N = 11)
DLCO (% predicted) 65.5 (53.0, 77.0)
(N = 30)
53.0 (46.0, 72.0)
(N = 10)
62.0 (53.0, 95.0)
(N = 9)
77.0 (53.0, 94.0)
(N = 11)
RVSP (mmHg) 50.0 (36.0, 61.0)
(N = 31)
57.0 (31.0, 73.0)
(N = 7)
37.0 (22.0, 49.0)
(N = 11)
60.0 (47.0, 62.0)
(N = 13)
ET-1 (pg/mL) 2.7 (2.3, 5.1)
(N = 50)
3.1 (2.3, 3.9)
(N = 14)
2.2 (1.8, 2.7)
(N = 15)
4.4 (2.5, 6.0)
(N = 21)
NT-proBNP (pg/mL) 289.0 (119.0, 592.0)
(N = 53)
386.0 (119.0, 661.0)
(N = 15)
264.0 (89.5, 541.0)
(N = 16)
297.0 (125.0, 592.0)
(N = 22)
RDW (%) 14.6 (13.9, 16.5)
(N = 51)
15.1 (14.2, 16.4)
(N = 15)
14.4 (13.5, 15.0)
(N = 15)
15.4 (14.2, 16.8)
(N = 21)
cGMP (pmoles/mL) 51.0 (36.0, 120.3)
(N = 48)
41.3 (33.1, 109.8)
(N = 13)
60.7 (33.3, 121.3)
(N = 15)
51.0 (39.4, 115.7)
(N = 20)
SNO-Hb (moles SNO/mole Hb) 0.0011 (0.0008, 0.0019)
(N = 36)
0.0008 (0.0005, 0.0011)
(N = 10)
0.0010 (0.0008, 0.0014)
(N = 12)
0.0017 (0.0011, 0.0021)
(N = 14)
cGMP to NTproBNP ratio (pmoles/pg) 0.25 (0.10, 0.63)
(N = 43)
0.23 (0.10, 0.66)
(N = 12)
0.29 (0.05, 0.69)
(N = 14)
0.27 (0.11, 0.41)
(N = 17)
ADMA (nM) 520.0 (446.0, 563.0)
(N = 53)
550.5 (500.0, 556.0)
(N = 14)
526.5 (442.5, 594.0)
(N = 16)
515.0 (432.0, 565.0)
(N = 23)
SDMA (nM) 413.0 (352.7, 493.5)
(N = 50)
352.7 (327.0, 402.2)
(N = 13)
453.6 (411.2, 521.0)
(N = 14)
424.9 (353.6, 500.0)
(N = 23)
NO2- (nM) 51.2 (34.1, 98.2)
(N = 30)
72.6 (41.0, 163.4)
(N = 10)
39.0 (26.5, 53.2)
(N = 8)
46.9 (35.0, 93.0)
(N = 12)
  1. Continuous variables presented as median (25, 75); categorical variables presented as frequency (proportion)
  2. ERA, endothelin receptor antagonist; PDE5i, phosphodiesterase 5 inhibitor; sGC, soluble guanylate cyclase stimulator; PAH, pulmonary arterial hypertension; 6MWD, six minute walk distance; m, meters; mPAP, mean pulmonary artery pressure; PVR, pulmonary vascular resistance; WU, woods units; RVSP, right ventricular systolic pressure
  3. a2/17 (11.8%) patients on therapy with soluble guanylate cyclase stimulator, the remainder on PDE5i
  4. b1/25 (4.0%) on therapy with soluble guanylate cyclase stimulator instead of PDE5i